RecruitingPhase 2NCT04915248
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Studying Plasmablastic lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Andrés Ferreri, Dr.Unità Linfomi - Dipartimento Oncoematologia -Istituto Scientifico San Raffaele - Milano
- Intervention
- Daratumumab(drug)
- Enrollment
- 28 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (18)
- A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona, Ancona, Italy
- Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati, Aviano, Italy
- A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
- Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Florence, Italy
- Milano - ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Miano, Italy
- Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia, Milan, Italy
- Monza - ASST MONZA Ospedale S. Gerardo - Ematologia, Monza, Italy
- Napoli - AORN - Azienda Ospedaliera dei Colli Monald - U.O.C. Oncologia, Naples, Italy
- U.O. Ematologia AO di Padova, Padua, Italy
- A.O. Universitaria Policlinico Giaccone Di Palermo, Palermo, Italy
- Ematologia IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy
- AO Arcispedale S.Maria Nuova Ematologia, Reggio Emilia, Italy
- Roma - IRCCS Spallanzani - Servizio di Ematologia in malattie infettive, Roma, Italy
- Roma - Ospedale S. Camillo - Ematologia, Roma, Italy
- A.O. S. Maria di Terni - S.C. Oncoematologia, Terni, Italy
- +3 more locations on ClinicalTrials.gov
Collaborators
Janssen-Cilag S.p.A.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04915248 on ClinicalTrials.govOther trials for Plasmablastic lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06781359Study on Plasmablastic Lymphoma PatientsFondazione Italiana Linfomi - ETS
- RECRUITINGEARLY PHASE1NCT04139304A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaAIDS Malignancy Consortium
- ACTIVE NOT RECRUITINGPHASE1NCT01961063Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaCity of Hope Medical Center